Sitemap
-
News list
- Global Investor Forum Life Science in Maastricht
- ILYA Pharma won the ATTD Startup grant
- ILYA Pharma receives a grant from VINNOVA
- PharmabioticsGlobal 2017
- ILYA Pharma presents at NGM Live tomorrow May 16
- Professor Mia Phillipson in the studio at the presentation of the Nobel Prize Laureates in Physiology or Medicine
- ILYA Pharma wins SweLife Accelerator grant
- Ilya Pharma is awarded three million euros from H2020 EU SME programme
- The innovation and the MOA published by high ranking scientific journal PNAS
- The CEO of Ilya Pharma ranked #20 top entrepreneur in Sweden
- Ilya Pharma in the hot spot
- Female entrepreneurs leading the way
- SwedenBIO Award 2018
- New project manager
- Celebration of safety- and efficacy data from the last preclinical study
- ILYA Pharma will present at the Nordic Life Science Days
- ILYA Pharma is growing and recruiting
- A platform for new biologics and technology innovations
- Ilya Pharma raises additional Euro 3 million to take novel ATMP through to Phase II for wound care
- Ilya Pharma is presenting at "INNOVATIONS IN WOUND HEALING 2018" FL 7-10 dec.
- Ilya Pharma is opening a new indication and recruits a post doctoral scientist with focus on IBD
- Selected top 500 globally of emerging companies in deep tech, Hello Tomorrow challenge
- Evonik 2019
- EIC Investor Day@Nasdaq
- Advanced Wound Care Seminar Redeye in Stockholm
- Hello Tomorrow Investor day
- Ilya Pharma winner at Hello Tomorrow Global Challenge 2019
- Ilya Pharma will present at the 29th Conference of the European Wound Management Association, Gothenburg 5-7 June
- Ilya Pharma will present at Nordic Life Science Days 11-12 September, Malmö
- Ilya Pharma selected to present at Biopharm America/Boston Biotech week 9-12 September
- Ilya Pharma - one of the selected 30 most innovative companies, RESI2019, Boston Biotech Week
- Ilya Pharma will present clinical developments at Bio Investor Forum SF 22-23 October
- Ilya Pharma selected top Innovator and will present at the New England Venture Summit December 4 in Boston
- Ilya Pharma will present new data and development plans for our ILP100 candidate at IBD Innovate, organised by Chrones and Colitis Foundation, NYC 4th of December
- Evelina Vågesjö and the achievements of Ilya Pharma recognised by MIT Tech Review Innovators under 35
- Ilya Pharma selected to present at the IMCAS Congress Innovation Shark Tank in Paris, 31st Jan 2020
- Ilya Pharma will present recent clinical data at Advanced Therapies Congress & Expo 2020 in London March 31
- Ilya Pharma will present developments at SwissNordicBio 6th of February 2020 in Zuric
- Ilya Pharma selected to present at the BIO CEO Investor forum in NYC 10-11th of February.
- Ilya Pharma’s ILP100 Phase I wound care therapy trial progresses swiftly to multiple dosing
- COVID-19
- Operational Report Q1 2020
- Resuming recruitment to the ongoing clinical trial - final cohorts
- Ilya Pharma awarded Euros 5.3 million from EIC Accelerator to fast track Phase II study of first-in-class ILPI100 advanced therapy for wound treatment in people with diabetes
- Ilya Pharma awarded risk-shared funding by EIT Health
- Operational Report Q2 2020
- Meet Margareth Jorvid - leading innovations to products
- Some thoughts from the CEO
- Meet Ingemar Kihlstörm - facilitating the next stage of growth
- Operational Report Q3 2020
- FDA open to new endpoints for patients with difficult wounds
- Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December
- Ilya Pharma will present at the Swiss Nordic Bio 10-11 February 2021
- Meet Stefan Roos co-founder and innovator for multiple patents of commercial strains of lactic acid bacteria
- Ilya Pharma extends research collaboration with Uppsala University
- Ilya Pharma presented at the Redeye unlisted event December 2
- Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II
- Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation
- Ilya Pharma awarded European patent covering engineered Lactobacillus reuteri strains for use in cutaneous wound therapy
- Ilya Pharma will present at Bio€quity Europe Digital 17-19 May
- Ilya Pharma will present at Nordic Life Science Invest Digital 19 April 2021
- Ilya Pharma will present recent clinical data and planned studies for ILP100 Topical and Oral at Pharmabiotics 28-29 April 2021
-
Media
- SårMagasinet
- New Swedish technology to cure chronic wounds
- Evelina Vågesjö in UNT
- Uppsala Innovation Center annual report 2014
- Mia Phillipson in Forskarpodden
- The Stockholm-Uppsala Life Science Investment Hotlist
- Evelina Vågesjö in Nya Horisonter
- Professor Mia Phillipson in "Secret lives of cells" from Wallenbergstiftelsen
- SweLife highlights ILYA Pharmas technology and clinical aspirations
- CEO Evelina Vågesjö gives a presentation and an interview at NGM
- ILYA Pharma closes first round of private investment
- Ilya Pharma appoints Ingemar Kihlström as Chairman of the Board
- Uppsala-a good place for Life Science companies
- Research behind ILYA Pharma's innovation featured in science TV programme
- New technology for accelerated wound healing discovered
- BioCentury recognises the clinical importance of the innovative next generation biologis developed by Ilya Pharma
- Our research applauded in Cell Host and Microbe
- Ilya Pharmas technology and vision featured in Manufacturing Chemist
- BioCentury Emerging Company Profile- WOUND-UP BACTERIA
- Ilya Pharma in Microbiome Times
- Ilya Pharma QnA in Biopharma Reporter
- Ilya Pharmas CEO interviewed by the Naked Scientist for BBC Radio
- Professor Mia Phillipson in prestigious scientific podcast describing the immune system and recent advances.
- Ilya Pharma interviewed in seminar of of climate for growth companies in Uppsala County
- Manufacturing Chemist highlights clinical developments of ILP100
- Ilya Pharma interviewed by the real estate company Vasakronan, facilitating growth of companies in Uppsala Science Park
- Ilya Pharmas technology explained in a nice conversation in - Discovery Matters
- Ilya Pharma receives Bio-X grant to complete preclinical work for novel IBD chemokine-based gene therapy candidates
- Four young Nordic life science entrepreneurs wins prestigious award
- Ilya Pharma selected for Springboard’s Health Innovation Hub
- H2020 SME Instrument phase II, WHILYAS-1, successfully completed
- Life Science Sweden recognizes Ilya Pharma
- Ilya Pharma Awarded 5.3 million EUR
- Co-founder of Ilya Pharma shortlisted for pioneering achievements in bringing game-changing innovation to clinical proof of concept.
- First Word Pharma shares news about the first granted US patent for the ILP-technolgy
- Completed recruitment in phase I study for ILP100-Topical published in First Word Pharma
- Immunology week hosted by Swedish TV
- The developments of ILP100 as a new-to-the world drug candidate in cell-and gene therapy featured in Authority Magazine
- Close up with CEO Evelina Vågesjö in Nordic Life Science Magazine #4
- Ilya Pharma extends research collaboration with Uppsala University
- Positive results from Ilya’s Phase I trial
- Firstword Pharma shares news of Ilyas awarded EU patent
- First in human data with ILP100-Topical picked up by Drug Discovery World - turning science into business
- Coverage in BioProcess International of our recent clinical data and how we work with development and industrialisation of the ILP100 in topical and oral formulations to adress important unmet medical needs
- Evelina Vågesjö CEO of Ilya Pharma included in the 2021 Power List in Advanced therapies by the Medicine Maker
- Blood flow regulating Macrophages, the science behind the scalable iLP-technology platform and lead candidate ILP100 published in Circulation Research
- Science of the MOA and benefits of CXCL12 to accelerate healing highlighted in Nature Cardiology Reviews
- About cookies
- Personer